Lynnette Averill, Ph.D., a clinical psychologist affiliated with the Baylor College of Medicine, Yale University, and the Department of Veterans Affairs, studies the causes and consequences of trauma-related psychopathology and suicidality, and is investigating novel rapid-acting interventions. She explains her special interest in the role that ketamine and psychedelics (including psilocybin and MDMA) could play treating veterans and others with severe PTSD who are at high risk for suicidal thoughts and behaviors.
Read More
Our PATHWAYS TO THE FUTURE story is about an unconventional approach to developing new psychiatric drugs. Based on an initiative by the National Institute of Mental Health, it’s called “Fast-Fail” and is designed to weed out the weakest drug candidates early in the process, to save time and money. In its first comprehensive test, a team led by two BBRF grantees and including 11 other BBRF grantees, Scientific Council members and prize winners, demonstrated the approach using a potential drug to treat anhedonia—the inability to experience or seek pleasure—which is seen in a number of psychiatric disorders including depression, anxiety, and PTSD.
Read More
A World Expert Discusses What Research and Personal Experience Have Taught Him
Read More
Foundation President and CEO, Jeffrey Borenstein, M.D. is quoted in an article from Scientific American about a research study featured in the Foundation's top 10 research advancements of 2016.
Read More
Allen Zeitlin is a third year med student at Michigan State University in Grand Rapids, with interests in psychiatry and neurology. This has a lot to do with the time he spent in the Middle East, serving in the military.
Read More